Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

JRNYS vs Revive Meds

JRNYS
Graded #267

Higher grade

vs+5.600000000000001
Revive Meds
Graded #404

Lower grade

The verdict

JRNYS takes it — 62.5/100 to 56.9/100.

JRNYS grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. JRNYS is a telehealth weight-loss membership built around branded GLP-1 medications, and the membership itself buys no medication.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueJRNYS +24
45
21
Dose & formulationRevive Meds +6
58
64
Clinical oversightJRNYS +4
84
80
Labs & monitoringJRNYS +19
71
52
FulfillmentRevive Meds +25
65
90
Contract termsJRNYS +2
55
53
JRNYS · left barRevive Meds · right bar

The numbers

MetricJRNYSRevive Meds
WeighScore62.5/10056.9/100
GradeCC
Scorecard rank#267#404
SemaglutideNot disclosed$369/mo (starting dose, compounded)
TirzepatideNot disclosed$459/mo (starting dose, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
JRNYS

Graded #267 · C

Strengths

  • Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
  • The membership band is published before intake and is banded openly by level of coach support
  • Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
  • Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
  • Members with commercial insurance may pay around $25 a month for the medication after any deductible

Where it loses points

  • The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
  • No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
  • The best case depends on commercial insurance coverage; without it the medication cost is unknown
  • No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
  • The states it can prescribe in are not published
Revive Meds

Graded #404 · C

Strengths

  • Offers both compounded semaglutide and dual-agonist tirzepatide, each combined with vitamin B12 (cyanocobalamin) in a single injection
  • Pay-per-order model with no subscription, sign-up fees, or long-term commitment, and free shipping on every order
  • Names its six 503A compounding pharmacies and two prescribing physicians, which is unusually transparent on fulfillment
  • Available in all 50 states and HSA/FSA eligible through a Medical Necessity Letter
  • Prepaying 3 to 12 months cuts the effective cost to as low as $202/mo (semaglutide) or $300/mo (tirzepatide)

Where it loses points

  • Month-to-month pricing is steep: $369/mo semaglutide and $459/mo tirzepatide unless you prepay several months
  • No public price list; pricing appears only after you complete a full health intake and create an account
  • Not LegitScript-certified (no seal displayed on the site)
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard